NCT06329882CompletedPhase 1/2
Doxycycline in Type II Diabetes
Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 9 Mar 2024
- Start date
- 30 Mar 2024
- Primary completion date
- 20 Mar 2026
- Lead sponsor
- Mostafa Bahaa
- Diseases
- Type 2 diabetes
- NCT number
- NCT06329882
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 60
- From 30 Mar 2024 to the primary completion date, 20 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation
Who the study is looking for
- Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5
Age in the registry: 40 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta Unuversity Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.